As previously announced, CMS approved use of Healthcare Common Procedure Coding System Code K1007 to bill Medicare for the Ekso Indego Personal. This code can also be used by other public health insurance programs as well as private payers.
“There are clinically demonstrated advantages for individuals with SCI who train with Ekso’s Indego Personal device in post-acute care that help improve their quality of life,” said
Ekso Indego Personal is a modular, lightweight and easily portable exoskeleton that is safe for use in most home and community environments. The device contains an advanced gait mode where the individual can reach faster walking speeds, granting them a new level of independence.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements include, without limitation, the increase in potential patient population as a result of CMS reimbursement and the Company’s ability to successfully sell its products to such customers and the impacts to patients from the Company’s devices. Forward-looking statements can be identified by words such as “expect,” “continue,” “anticipate,” “estimate,” “believe,” “plan,” “projection,” “grow,” “potential,” “future,” “can,” “develop,” “proposition,” “position,” “expand,” “may” or words of similar meaning. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, a future change to the reimbursement amount and less demand than expected from patients even at a reduced purchase price. These and other factors are identified and described in more detail in the Company's public filings with the
Contact:
David Carey
212-867-1768
investors@eksobionics.com
Source:
2024 GlobeNewswire, Inc., source